While uptake has been limited, cell therapy’s impact in cancer care is growing, and biotech companies have continued to invest in ways to improve it, such as through “off-the-shelf” options. Discover the current market for cancer cell therapies and what biotechs are working on next.
INCLUDED IN THIS TRENDLINE
- Roche digs into off-the-shelf cell therapy with Poseida deal
- Bristol Myers CAR-T therapy cleared by FDA for earlier lymphoma use
- Versant-backed startup launches with plans to broaden cell therapy’s reach